Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2021
CMA fines Advanz over thyroid tablet pricing
Fine or penalty
The UK Competition and Markets Authority imposed fines of more than £100 million on Advanz and its former private equity owners after finding that Advanz charged excessive and unfair prices for liothyronine tablets.
Source excerpt
The UK’s competition watchdog has imposed fines of more than £100m on the pharmaceutical company Advanz and its former private equity owners after it was found to have inflated the price of its thyroid tablets by up to 6,000%.
An investigation by the Competition and Markets Authority (CMA) found that the private-equity backed pharmaceutical company charged “excessive and unfair prices” for liothyronine tablets, which are used to treat thyroid hormone deficiency.